查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2149715

2034年太空生物學和多體學市場預測——按分子模式、技術、多體學組合、產品和服務、樣本類型、應用和地區分類的全球分析

Spatial Biology & Multi-Omics Market Forecasts to 2034 - Global Analysis By Molecular Modality, Technology, Multi-Omic Combination, Product and Service, Sample Type, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

全球太空生物學和多組體學市場預計到 2026 年將達到 24 億美元，並在預測期內以 14.3% 的複合年成長率成長，到 2034 年達到 70 億美元。

太空生物學和多組體學是指能夠繪製完整組織樣本中多種生物分子空間分佈圖的先進分析技術。這些技術透過整合基因組、轉錄組、蛋白質組和代謝組數據，提供對細胞間相互作用和組織結構的全面理解。利用高解析度成像、定序和質譜技術，這些技術在分析複雜的生物系統時能夠維持空間資訊。透過運用這些技術，研究人員可以以前所未有的精確度揭示疾病機制、識別新的生物標記並開發標靶療法。

精準醫療的需求日益成長

隨著全球對精準醫療的關注度日益提高，研究人員被迫採用太空生物學和多組體學平台，以提供詳細的細胞分析選項。人們對腫瘤異質性和複雜疾病機制的認知不斷加深，正在加速這些技術與藥物研發框架的整合。影像解析度的提高為這一轉變提供了支持，增強了數據的準確性。因此，製藥公司正在投資多組體學技術，以在滿足療效標準的同時，最佳化療法研發成本。

設備和數據分析高成本

引進和運作先進空間生物學設備的高昂成本是其商業性化應用的主要障礙。建構高精度多組體學資料集通常需要複雜的成像流程和先進的生物資訊技術，從而推高了整體研究成本。此外，組織樣本製備的差異性也限制了標準化分析流程的可靠性。這些因素共同阻礙了市場擴張，尤其是在預算有限的小規模實驗室中。

癌症研究領域應用範圍的擴大

腫瘤微環境分析需求的不斷成長，為腫瘤研究領域的空間生物學和多體學服務提供者帶來了巨大的發展機會。以高解析度定序為主要輸入的先進成像平台，能夠在不破壞組織結構的前提下，有效率地繪製免疫細胞間的相互作用圖譜。隨著全球對癌症免疫療法的投資不斷增加，先進多組體學解決方案的應用預計將顯著成長。

與傳統批量定序的競爭

對傳統批量定序方法的持續依賴對空間生物學和多體學市場構成重大威脅。在目前的科學研究預算下，傳統的批量RNA定序和成熟的蛋白質體學檢測方法通常具有成本績效效益，對於大規模人群研究而言，它們可能是更經濟可行的選擇。此外，單細胞定序技術的快速發展提高了傳統細胞分析方法的效率。這種競爭可能會阻礙市場滲透。

新型冠狀病毒（COVID-19）的影響：

疫情初期，設施關閉擾亂了實驗室運作，延誤了研究計畫。然而，隨後對病毒致病性的快速了解需求加速了空間生物學平台在組織分析中的應用。疫情後，人們對感染疾病研究和免疫學的關注度提高，加強了對多組體學技術的長期投資，推動了全球學術界和製藥界多個領域的市場強勁復甦和擴張。

在預測期內，空間轉錄組學領域預計將佔據最大的市場規模。

由於空間轉錄組學在生物學研究中的基礎性和廣泛適用性，預計在預測期內，該領域將佔據最大的市場佔有率。空間轉錄組學平台具有卓越的基因表現圖譜繪製能力，並能有效分析複雜的組織切片。這顯著減少了常規研究方法中的資料遺失，並最大限度地降低了空間背景干擾。隨著業界日益重視精細的細胞分析技術，對專業轉錄組學工具的需求持續成長，鞏固了該領域在市場上的主導地位。

預計混合成像和定序技術領域在預測期內將呈現最高的複合年成長率。

在預測期內，混合成像和定序技術領域預計將呈現最高的成長率，這主要得益於光學和分子生物學融合技術的快速發展。這些技術能夠精確關聯形態學特徵，從而產生高度專業化且穩健的多組體學數據，並可應用於特定的疾病治療。透過先進的混合整合，提高資料解析度、操作擴充性和分析深度，將顯著提升製程經濟性，並加速全球商業性化應用。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這得益於其成熟的製藥產業和先進的研究基礎設施，這些基礎設施積極利用空間生物學和多組體學。該地區受益於大量的研發投入、健全的智慧財產權保護以及政府對醫療保健領域技術創新的支持。此外，美國和加拿大主要產業參與者對先進多組體學平台的早期應用，進一步鞏固了該地區的全球主導地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於新興經濟體製藥行業的快速現代化和生物技術行業的擴張。中國、印度和日本等國正在加大對研究基礎設施和多體學技術的投資，以滿足日益成長的國內醫療保健需求和日益嚴格的效率監管要求。此外，有利的政府政策、不斷成長的外國直接投資以及經濟高效的技術資源的可用性，正在加速全部區域空間生物學的應用。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需經可行性確認）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章：執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球空間生物學與多體學市場：依分子模式分類

  • 空間轉錄組學
  • 空間基因體學
  • 空間蛋白質體學
  • 空間表觀表觀基因
  • 空間代謝體學
  • 空間脂質體學
  • 其他分子模式

第6章 全球空間生物學與多體學市場：依技術分類

  • 基於定序的技術
  • 成像技術
  • 原位雜合反應技術
  • 多路成像技術
  • 基於質譜的技術
  • 混合成像和定序技術
  • 其他技術

第7章 全球空間生物學與多體學市場：依多體學組合分類

  • 轉錄組學和蛋白​​質組學
  • 轉錄組學和基因組學
  • 轉錄組學和表觀基因
  • 轉錄組學、蛋白質組學、基因組學
  • 轉錄組學、蛋白質組學、表觀基因
  • 轉錄組學、蛋白質組學、代謝體學
  • 整合多層組體學

第8章 全球空間生物學和多體學市場：按產品和服務分類

  • 設備和平台
  • 耗材和試劑
  • 檢測試劑盒
  • 軟體與生物資訊學
  • 數據分析服務
  • 樣品製備服務
  • 科學研究和實驗室用途服務

第9章 全球空間生物學與多體學市場：依樣本類型分類

  • 福馬林固定石蠟包埋（FFPE）樣本
  • 新鮮冷凍組織
  • 活組織
  • 細胞懸浮液
  • 器官類型和3D組織模型
  • 液態生物檢體檢體
  • 其他樣本類型

第10章 全球空間生物學與多組體學市場：按應用分類

  • 腫瘤學調查
  • 免疫學和腫瘤免疫學
  • 神經科學
  • 藥物發現與開發
  • 生物標記的發現
  • 細胞生物學和發育生物學
  • 感染疾病調查
  • 精準醫療
  • 其他用途

第11章 全球空間生物學與多體學市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第12章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第13章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第14章：公司簡介

  • 10x Genomics, Inc.
  • Bruker Corporation
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Quanterix Corporation
  • NanoString Technologies, Inc.
  • Standard BioTools Inc.
  • Akoya Biosciences, Inc.
  • Merck KGaA
  • Roche Holding AG
  • QIAGEN NV
  • Agilent Technologies, Inc.
  • Waters Corporation
  • Revvity, Inc.
  • Sartorius AG
  • Oxford Nanopore Technologies plc
  • Pacific Biosciences of California, Inc.
Product Code: SMRC40127

According to Stratistics MRC, the Global Spatial Biology & Multi-Omics Market is accounted for $2.4 billion in 2026 and is expected to reach $7.0 billion by 2034 growing at a CAGR of 14.3% during the forecast period. Spatial biology and multi-omics refer to advanced analytical techniques that map the spatial distribution of multiple biological molecules within intact tissue samples. They function by integrating genomic, transcriptomic, proteomic, and metabolomic data to provide a comprehensive understanding of cellular interactions and tissue architecture. These technologies utilize high-resolution imaging, sequencing, and mass spectrometry to preserve spatial context while analyzing complex biological systems. Their application enables researchers to uncover disease mechanisms, identify novel biomarkers, and develop targeted therapeutic interventions with unprecedented precision.

Market Dynamics:

Driver:

Rising Demand for Precision Medicine

The escalating global emphasis on precision medicine compels researchers to adopt spatial biology and multi-omics platforms offering detailed cellular analysis alternatives. Growing recognition of tumor heterogeneity and complex disease mechanisms is accelerating the integration of these technologies into drug development frameworks. This transition is supported by advancements in imaging resolution, which enhance data accuracy. Consequently, pharmaceutical firms are investing in multi-omics technologies to achieve compliance with efficacy benchmarks while optimizing therapeutic development costs.

Restraint:

High Instrumentation and Data Analysis Costs

The substantial expenses associated with acquiring and operating advanced spatial biology instruments represent a significant barrier to widespread commercial adoption. Developing highly accurate multi-omic datasets often requires complex imaging processes and sophisticated bioinformatics techniques, which escalate overall research costs. Furthermore, the variability in tissue sample preparation limits the operational reliability of standardized analytical pipelines. These factors collectively constrain market expansion, particularly for smaller laboratories with limited funding budgets.

Opportunity:

Expansion in Oncology Research Applications

The oncology research sector presents substantial growth opportunities for spatial biology and multi-omics providers due to increasing demand for tumor microenvironment analysis. Advanced imaging platforms offer a highly effective pathway to map immune cell interactions without destroying tissue architecture, utilizing high-resolution sequencing as primary inputs. As global investments in cancer immunotherapy expand, the adoption of advanced multi-omics solutions is expected to surge significantly.

Threat:

Competition from Traditional Bulk Sequencing

The continuous reliance on traditional bulk sequencing methodologies poses a considerable threat to the spatial biology and multi-omics market. Conventional bulk RNA sequencing and established proteomic assays often exhibit superior cost-effectiveness under current research budgets and can be more economically viable for large-scale population studies. Additionally, the rapid advancement of single-cell sequencing technologies is enhancing the efficiency of conventional cellular analysis methods. This competitive pressure may hinder market penetration.

Covid-19 Impact:

The pandemic initially disrupted laboratory operations and delayed research projects due to facility closures. However, the subsequent need for rapid viral pathogenesis understanding accelerated the adoption of spatial biology platforms for tissue analysis. Post-pandemic, the heightened focus on infectious disease research and immunology has reinforced long-term investments in multi-omics technologies, driving robust market recovery and expansion across diverse academic and pharmaceutical sectors globally.

The spatial transcriptomics segment is expected to be the largest during the forecast period

The spatial transcriptomics segment is expected to account for the largest market share during the forecast period, due to its foundational role and widespread applicability across diverse biological research environments. Spatial transcriptomics platforms offer exceptional gene expression mapping and operate effectively in analyzing complex tissue sections, which significantly reduces data loss and minimizes spatial context disruption in daily research processes. As industries increasingly prioritize detailed cellular analysis methods, the demand for specialized transcriptomics tools continues to surge, thereby solidifying its dominant market position.

The hybrid imaging-sequencing technologies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the hybrid imaging-sequencing technologies segment is predicted to witness the highest growth rate, driven by rapid advancements in optical engineering and molecular biology integration. These technologies enable the precise correlation of morphological features to produce highly specialized and robust multi-omic outputs tailored for specific disease applications. The ability to enhance data resolution, operational scalability, and analytical depth through advanced hybrid integration significantly improves process economics, accelerating commercial adoption globally.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to the presence of well-established pharmaceutical industries and advanced research infrastructure that heavily utilize spatial biology and multi-omics. The region benefits from substantial research and development investments, robust intellectual property protection, and supportive government initiatives promoting technological innovation in healthcare. Furthermore, the early adoption of advanced multi-omics platforms by key industry players in the United States and Canada reinforces the region's dominant position globally.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapid pharmaceutical modernization and expanding biotechnology sectors in emerging economies. Countries such as China, India, and Japan are increasingly investing in research infrastructure and multi-omics technologies to meet growing domestic healthcare demands and stringent efficiency regulations. Additionally, favorable government policies, rising foreign direct investment, and the availability of cost-effective technological resources are collectively driving the accelerated adoption of spatial biology across the region.

Key players in the market

Some of the key players in Spatial Biology & Multi-Omics Market include 10x Genomics, Inc., Bruker Corporation, Illumina, Inc., Thermo Fisher Scientific Inc., Danaher Corporation, Quanterix Corporation, NanoString Technologies, Inc., Standard BioTools Inc., Akoya Biosciences, Inc., Merck KGaA, Roche Holding AG, QIAGEN N.V., Agilent Technologies, Inc., Waters Corporation, Revvity, Inc., Sartorius AG, Oxford Nanopore Technologies plc, and Pacific Biosciences of California, Inc.

Key Developments:

In September 2026, 10x Genomics, Inc. launched a next-generation spatial transcriptomics platform optimized for high-resolution tissue mapping, achieving a thirty percent improvement in gene detection while significantly reducing sample preparation time requirements for global research laboratories.

In August 2026, Bruker Corporation expanded its mass spectrometry imaging capacity through a strategic partnership with a leading academic firm, enabling the scalable deployment of novel proteomic analysis modules for drug discovery.

In July 2026, Illumina, Inc. secured a major supply agreement to provide customized sequencing reagents for a prominent pharmaceutical company, facilitating the efficient integration of advanced multi-omic tools into next-generation therapeutic ecosystems globally.

Molecular Modalities Covered:

  • Spatial Transcriptomics
  • Spatial Genomics
  • Spatial Proteomics
  • Spatial Epigenomics
  • Spatial Metabolomics
  • Spatial Lipidomics
  • Other Molecular Modalities

Technologies Covered:

  • Sequencing-Based Technologies
  • Imaging-Based Technologies
  • In Situ Hybridization Technologies
  • Multiplexed Imaging Technologies
  • Mass Spectrometry-Based Technologies
  • Hybrid Imaging-Sequencing Technologies
  • Other Technologies

Multi-Omic Combinations Covered:

  • Transcriptomics and Proteomics
  • Transcriptomics and Genomics
  • Transcriptomics and Epigenomics
  • Transcriptomics, Proteomics and Genomics
  • Transcriptomics, Proteomics and Epigenomics
  • Transcriptomics, Proteomics and Metabolomics
  • Integrated Multi-Layer Omics

Product and Services Covered:

  • Instruments and Platforms
  • Consumables and Reagents
  • Assay Kits
  • Software and Bioinformatics
  • Data Analysis Services
  • Sample Preparation Services
  • Research and Laboratory Services

Sample Types Covered:

  • Formalin-Fixed Paraffin-Embedded Samples
  • Fresh Frozen Tissue
  • Fresh Tissue
  • Cell Suspensions
  • Organotypic and 3D Tissue Models
  • Liquid Biopsy Samples
  • Other Sample Types

Applications Covered:

  • Oncology Research
  • Immunology and Immuno-Oncology
  • Neuroscience
  • Drug Discovery and Development
  • Biomarker Discovery
  • Cell Biology and Developmental Biology
  • Infectious Disease Research
  • Precision Medicine
  • Other Applications

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Spatial Biology & Multi-Omics Market, By Molecular Modality

  • 5.1 Spatial Transcriptomics
  • 5.2 Spatial Genomics
  • 5.3 Spatial Proteomics
  • 5.4 Spatial Epigenomics
  • 5.5 Spatial Metabolomics
  • 5.6 Spatial Lipidomics
  • 5.7 Other Molecular Modalities

6 Global Spatial Biology & Multi-Omics Market, By Technology

  • 6.1 Sequencing-Based Technologies
  • 6.2 Imaging-Based Technologies
  • 6.3 In Situ Hybridization Technologies
  • 6.4 Multiplexed Imaging Technologies
  • 6.5 Mass Spectrometry-Based Technologies
  • 6.6 Hybrid Imaging-Sequencing Technologies
  • 6.7 Other Technologies

7 Global Spatial Biology & Multi-Omics Market, By Multi-Omic Combination

  • 7.1 Transcriptomics and Proteomics
  • 7.2 Transcriptomics and Genomics
  • 7.3 Transcriptomics and Epigenomics
  • 7.4 Transcriptomics, Proteomics and Genomics
  • 7.5 Transcriptomics, Proteomics and Epigenomics
  • 7.6 Transcriptomics, Proteomics and Metabolomics
  • 7.7 Integrated Multi-Layer Omics

8 Global Spatial Biology & Multi-Omics Market, By Product and Service

  • 8.1 Instruments and Platforms
  • 8.2 Consumables and Reagents
  • 8.3 Assay Kits
  • 8.4 Software and Bioinformatics
  • 8.5 Data Analysis Services
  • 8.6 Sample Preparation Services
  • 8.7 Research and Laboratory Services

9 Global Spatial Biology & Multi-Omics Market, By Sample Type

  • 9.1 Formalin-Fixed Paraffin-Embedded Samples
  • 9.2 Fresh Frozen Tissue
  • 9.3 Fresh Tissue
  • 9.4 Cell Suspensions
  • 9.5 Organotypic and 3D Tissue Models
  • 9.6 Liquid Biopsy Samples
  • 9.7 Other Sample Types

10 Global Spatial Biology & Multi-Omics Market, By Application

  • 10.1 Oncology Research
  • 10.2 Immunology and Immuno-Oncology
  • 10.3 Neuroscience
  • 10.4 Drug Discovery and Development
  • 10.5 Biomarker Discovery
  • 10.6 Cell Biology and Developmental Biology
  • 10.7 Infectious Disease Research
  • 10.8 Precision Medicine
  • 10.9 Other Applications

11 Global Spatial Biology & Multi-Omics Market, By Geography

  • 11.1 North America
    • 11.1.1 United States
    • 11.1.2 Canada
    • 11.1.3 Mexico
  • 11.2 Europe
    • 11.2.1 United Kingdom
    • 11.2.2 Germany
    • 11.2.3 France
    • 11.2.4 Italy
    • 11.2.5 Spain
    • 11.2.6 Netherlands
    • 11.2.7 Belgium
    • 11.2.8 Sweden
    • 11.2.9 Switzerland
    • 11.2.10 Poland
    • 11.2.11 Rest of Europe
  • 11.3 Asia Pacific
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 South Korea
    • 11.3.5 Australia
    • 11.3.6 Indonesia
    • 11.3.7 Thailand
    • 11.3.8 Malaysia
    • 11.3.9 Singapore
    • 11.3.10 Vietnam
    • 11.3.11 Rest of Asia Pacific
  • 11.4 South America
    • 11.4.1 Brazil
    • 11.4.2 Argentina
    • 11.4.3 Colombia
    • 11.4.4 Chile
    • 11.4.5 Peru
    • 11.4.6 Rest of South America
  • 11.5 Rest of the World (RoW)
    • 11.5.1 Middle East
      • 11.5.1.1 Saudi Arabia
      • 11.5.1.2 United Arab Emirates
      • 11.5.1.3 Qatar
      • 11.5.1.4 Israel
      • 11.5.1.5 Rest of Middle East
    • 11.5.2 Africa
      • 11.5.2.1 South Africa
      • 11.5.2.2 Egypt
      • 11.5.2.3 Morocco
      • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

  • 12.1 Industry Value Network and Supply Chain Assessment
  • 12.2 White-Space and Opportunity Mapping
  • 12.3 Product Evolution and Market Life Cycle Analysis
  • 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

  • 13.1 Mergers and Acquisitions
  • 13.2 Partnerships, Alliances, and Joint Ventures
  • 13.3 New Product Launches and Certifications
  • 13.4 Capacity Expansion and Investments
  • 13.5 Other Strategic Initiatives

14 Company Profiles

  • 14.1 10x Genomics, Inc.
  • 14.2 Bruker Corporation
  • 14.3 Illumina, Inc.
  • 14.4 Thermo Fisher Scientific Inc.
  • 14.5 Danaher Corporation
  • 14.6 Quanterix Corporation
  • 14.7 NanoString Technologies, Inc.
  • 14.8 Standard BioTools Inc.
  • 14.9 Akoya Biosciences, Inc.
  • 14.10 Merck KGaA
  • 14.11 Roche Holding AG
  • 14.12 QIAGEN N.V.
  • 14.13 Agilent Technologies, Inc.
  • 14.14 Waters Corporation
  • 14.15 Revvity, Inc.
  • 14.16 Sartorius AG
  • 14.17 Oxford Nanopore Technologies plc
  • 14.18 Pacific Biosciences of California, Inc.

List of Tables

  • Table 1 Global Spatial Biology & Multi-Omics Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Spatial Biology & Multi-Omics Market Outlook, By Molecular Modality (2023-2034) ($MN)
  • Table 3 Global Spatial Biology & Multi-Omics Market Outlook, By Spatial Transcriptomics (2023-2034) ($MN)
  • Table 4 Global Spatial Biology & Multi-Omics Market Outlook, By Spatial Genomics (2023-2034) ($MN)
  • Table 5 Global Spatial Biology & Multi-Omics Market Outlook, By Spatial Proteomics (2023-2034) ($MN)
  • Table 6 Global Spatial Biology & Multi-Omics Market Outlook, By Spatial Epigenomics (2023-2034) ($MN)
  • Table 7 Global Spatial Biology & Multi-Omics Market Outlook, By Spatial Metabolomics (2023-2034) ($MN)
  • Table 8 Global Spatial Biology & Multi-Omics Market Outlook, By Spatial Lipidomics (2023-2034) ($MN)
  • Table 9 Global Spatial Biology & Multi-Omics Market Outlook, By Other Molecular Modalities (2023-2034) ($MN)
  • Table 10 Global Spatial Biology & Multi-Omics Market Outlook, By Technology (2023-2034) ($MN)
  • Table 11 Global Spatial Biology & Multi-Omics Market Outlook, By Sequencing-Based Technologies (2023-2034) ($MN)
  • Table 12 Global Spatial Biology & Multi-Omics Market Outlook, By Imaging-Based Technologies (2023-2034) ($MN)
  • Table 13 Global Spatial Biology & Multi-Omics Market Outlook, By In Situ Hybridization Technologies (2023-2034) ($MN)
  • Table 14 Global Spatial Biology & Multi-Omics Market Outlook, By Multiplexed Imaging Technologies (2023-2034) ($MN)
  • Table 15 Global Spatial Biology & Multi-Omics Market Outlook, By Mass Spectrometry-Based Technologies (2023-2034) ($MN)
  • Table 16 Global Spatial Biology & Multi-Omics Market Outlook, By Hybrid Imaging-Sequencing Technologies (2023-2034) ($MN)
  • Table 17 Global Spatial Biology & Multi-Omics Market Outlook, By Other Technologies (2023-2034) ($MN)
  • Table 18 Global Spatial Biology & Multi-Omics Market Outlook, By Multi-Omic Combination (2023-2034) ($MN)
  • Table 19 Global Spatial Biology & Multi-Omics Market Outlook, By Transcriptomics and Proteomics (2023-2034) ($MN)
  • Table 20 Global Spatial Biology & Multi-Omics Market Outlook, By Transcriptomics and Genomics (2023-2034) ($MN)
  • Table 21 Global Spatial Biology & Multi-Omics Market Outlook, By Transcriptomics and Epigenomics (2023-2034) ($MN)
  • Table 22 Global Spatial Biology & Multi-Omics Market Outlook, By Transcriptomics, Proteomics and Genomics (2023-2034) ($MN)
  • Table 23 Global Spatial Biology & Multi-Omics Market Outlook, By Transcriptomics, Proteomics and Epigenomics (2023-2034) ($MN)
  • Table 24 Global Spatial Biology & Multi-Omics Market Outlook, By Transcriptomics, Proteomics and Metabolomics (2023-2034) ($MN)
  • Table 25 Global Spatial Biology & Multi-Omics Market Outlook, By Integrated Multi-Layer Omics (2023-2034) ($MN)
  • Table 26 Global Spatial Biology & Multi-Omics Market Outlook, By Product and Service (2023-2034) ($MN)
  • Table 27 Global Spatial Biology & Multi-Omics Market Outlook, By Instruments and Platforms (2023-2034) ($MN)
  • Table 28 Global Spatial Biology & Multi-Omics Market Outlook, By Consumables and Reagents (2023-2034) ($MN)
  • Table 29 Global Spatial Biology & Multi-Omics Market Outlook, By Assay Kits (2023-2034) ($MN)
  • Table 30 Global Spatial Biology & Multi-Omics Market Outlook, By Software and Bioinformatics (2023-2034) ($MN)
  • Table 31 Global Spatial Biology & Multi-Omics Market Outlook, By Data Analysis Services (2023-2034) ($MN)
  • Table 32 Global Spatial Biology & Multi-Omics Market Outlook, By Sample Preparation Services (2023-2034) ($MN)
  • Table 33 Global Spatial Biology & Multi-Omics Market Outlook, By Research and Laboratory Services (2023-2034) ($MN)
  • Table 34 Global Spatial Biology & Multi-Omics Market Outlook, By Sample Type (2023-2034) ($MN)
  • Table 35 Global Spatial Biology & Multi-Omics Market Outlook, By Formalin-Fixed Paraffin-Embedded Samples (2023-2034) ($MN)
  • Table 36 Global Spatial Biology & Multi-Omics Market Outlook, By Fresh Frozen Tissue (2023-2034) ($MN)
  • Table 37 Global Spatial Biology & Multi-Omics Market Outlook, By Fresh Tissue (2023-2034) ($MN)
  • Table 38 Global Spatial Biology & Multi-Omics Market Outlook, By Cell Suspensions (2023-2034) ($MN)
  • Table 39 Global Spatial Biology & Multi-Omics Market Outlook, By Organotypic and 3D Tissue Models (2023-2034) ($MN)
  • Table 40 Global Spatial Biology & Multi-Omics Market Outlook, By Liquid Biopsy Samples (2023-2034) ($MN)
  • Table 41 Global Spatial Biology & Multi-Omics Market Outlook, By Other Sample Types (2023-2034) ($MN)
  • Table 42 Global Spatial Biology & Multi-Omics Market Outlook, By Application (2023-2034) ($MN)
  • Table 43 Global Spatial Biology & Multi-Omics Market Outlook, By Oncology Research (2023-2034) ($MN)
  • Table 44 Global Spatial Biology & Multi-Omics Market Outlook, By Immunology and Immuno-Oncology (2023-2034) ($MN)
  • Table 45 Global Spatial Biology & Multi-Omics Market Outlook, By Neuroscience (2023-2034) ($MN)
  • Table 46 Global Spatial Biology & Multi-Omics Market Outlook, By Drug Discovery and Development (2023-2034) ($MN)
  • Table 47 Global Spatial Biology & Multi-Omics Market Outlook, By Biomarker Discovery (2023-2034) ($MN)
  • Table 48 Global Spatial Biology & Multi-Omics Market Outlook, By Cell Biology and Developmental Biology (2023-2034) ($MN)
  • Table 49 Global Spatial Biology & Multi-Omics Market Outlook, By Infectious Disease Research (2023-2034) ($MN)
  • Table 50 Global Spatial Biology & Multi-Omics Market Outlook, By Precision Medicine (2023-2034) ($MN)
  • Table 51 Global Spatial Biology & Multi-Omics Market Outlook, By Other Applications (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.